- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07259681
Microbioma Intestinale in Pazienti con Cancro Ginecologico con Tossicità Pelvica: Confronto con i Controlli e Effetto dell'Ozono Retale. (MicrOzoGineTox). (MicrOGineTox)
Profili del Microbioma Intestinale in Donne con Tumori Ginecologici e Tossicità Pelvica Secondaria a Radioterapia e Chemioterapia: Confronto con i Controlli ed Effetto del Trattamento con Ozono Rettale.
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Panoramica dello studio
Stato
Descrizione dettagliata
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Bernardino Clavo, MD, PhD
- Numero di telefono: 34928449278
- Email: bernardinoclavo@gmail.com
Backup dei contatti dello studio
- Nome: Francisco Rodríguez-Esparragón, BSc, PhD
- Numero di telefono: 34928449288
- Email: afrodesp@gmail.com
Luoghi di studio
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Spagna, 35019
- Reclutamento
- Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
-
Contatto:
- Bernardino Clavo, MD, PhD
- Numero di telefono: 34928449278
- Email: bernardinoclavo@gmail.com
-
Contatto:
- Francisco Rodríguez-Esparragón, BSc, PhD
- Numero di telefono: 34928449288
- Email: afrodesp@gmail.com
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Spagna, 38296
- Reclutamento
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
-
Contatto:
- Jacob Lorenzo-Morales, Prof
- Numero di telefono: 34922318402
- Email: jmlorenz@ull.edu.es
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).
Descrizione
Inclusion Criteria for all patients (Cases and Controls):
-
Adult women (>=18 years).
-
Diagnosed with gynecological tumors (any location and stage).
-
Previously treated with radiotherapy and/or chemotherapy.
-
Must accept and sign the specific informed consent for this study.
Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):
-
Must present chronic TPIRQT with >= 3 months of duration after habitual symptomatic treatment.
-
Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale.
Exclusion Criteria for all patients (Cases and Controls):
- Not meeting all inclusion criteria.
- Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota.
- Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results.
- Unwillingness or inability to provide written informed consent for study participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
TPIRQT Group (Cases)
Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy |
|
Control Group
pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups
Lasso di tempo: Baseline (single time point for controls, pre-ozone for cases)
|
Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT. |
Baseline (single time point for controls, pre-ozone for cases)
|
|
Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.
Lasso di tempo: Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing. |
Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
|
Correlation of gut microbiome profile with grade of pelvic toxicity.
Lasso di tempo: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation of gut microbiome profile with health-related quality of life (HRQoL).
Lasso di tempo: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with anxiety and depression levels.
Lasso di tempo: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.
Lasso di tempo: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Bernardino Clavo, MD, PhD, Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- Investigatore principale: Francisco Rodríguez-Esparragón, BSc, PhD, Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- Investigatore principale: Jacob Lorenzo-Morales, Prof, Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad La Laguna
Pubblicazioni e link utili
Pubblicazioni generali
- Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015.
- Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, Ran J, Hou X, Geng Y, Yang Z, Feng S, Li C, Zhao X. The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review. Radiat Oncol. 2021 Sep 25;16(1):187. doi: 10.1186/s13014-021-01899-y.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment. Pain Med. 2021 Sep 8;22(9):2138-2141. doi: 10.1093/pm/pnaa459. No abstract available.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. J Palliat Med. 2021 Jan;24(1):97-102. doi: 10.1089/jpm.2019.0597. Epub 2020 May 5.
- Clavo B, Ceballos D, Gutierrez D, Rovira G, Suarez G, Lopez L, Pinar B, Cabezon A, Morales V, Oliva E, Fiuza D, Santana-Rodriguez N. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy. J Pain Symptom Manage. 2013 Jul;46(1):106-12. doi: 10.1016/j.jpainsymman.2012.06.017. Epub 2012 Oct 26.
- Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479.
- Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18.
- Li L, Yang Z, Yi Y, Song Y, Zhang W. Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies. Gut Microbes. 2025 Dec;17(1):2528429. doi: 10.1080/19490976.2025.2528429. Epub 2025 Jul 6.
- Ma CY, Zhao J, Xu XT, He XL, Qin SB, Zhou JY. Predictive biomarkers in the gut microbiome and metabolome for severe acute radiation enteritis in cervical cancer radiotherapy. Discov Oncol. 2025 Jul 1;16(1):1220. doi: 10.1007/s12672-025-03077-y.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2025-436-1
- PIFIISC25/52 (Altro numero di sovvenzione/finanziamento: FIISC (Fundación Canaria Inst. Investig. Sanitaria Canarias))
- CIGC'25/26 (Altro numero di sovvenzione/finanziamento: Cabildo de Gran Canaria (CIGC))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
- It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
- Data will be available after publication, ending 36 months following article publication.
- They will be available for investigators whose proposed use of the data has been apd by an independent review committee identified for this purpose.
Periodo di condivisione IPD
Data will be available after publication, ending 36 months following article publication.
Criteri di accesso alla condivisione IPD
They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .